Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes oneither no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas

Next Previous
Trial Profile

A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes oneither no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary) ; Antihyperglycaemics
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms INSIGHT
  • Sponsors Sanofi

Most Recent Events

  • 01 Apr 2018 Results of pooled analysis of Asian patients included in this and other six trials assessing the impact of patient baseline covariates on the required dose of basal insulin and treatment response for the improved management of Asian patients with type 2 diabetes published in the Diabetes Therapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top